IRB Study Number 21-408
Status Recruiting
Institute Taussig Cancer Institute
Description
Primary Objective:
To assess rates of Grade 3 and greater acute toxicity.
Secondary Objectives:
i. Assess rates of grade 2 acute toxicity based on CTCAE version 5.
ii. Assess rates of grade 2 and greater chronic toxicity based on CTCAE version 5.
iii. Assess clinical outcomes (local control, regional recurrence, distant metastases).
iv. Compare clinical outcomes and toxicities to historical controls.
Inclusion Criteria
i. Patients with histologically confirmed retroperitoneal sarcoma
High grade liposarcoma
Threatened surgical margin (as judged by surgeon) or recurrences not having previously received RT are also eligible
ii. Treatment plan includes neoadjuvant radiation followed by surgery
- As determined by multi-disciplinary sarcoma team
iii. Age > 18 years old, no upper age limit
Exclusion Criteria
i. Metastatic disease
ii. Lack of histologic diagnosis
iii. Unresectable disease
